Jacobs Levy Equity Management, Inc Adagio Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 547,290 shares of ADGI stock, worth $1.81 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
547,290
Previous 687,938
20.44%
Holding current value
$1.81 Million
Previous $2.28 Million
20.47%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding ADGI
# of Institutions
78Shares Held
63.8MCall Options Held
2.3KPut Options Held
2.1K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.81% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.34% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million29.1% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$14.5 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...